Dr Reddy's launches five generics in US
This article was originally published in Scrip
Dr Reddy's Laboratories launched five generic products in the US last month. These are levetiracetam tablets 250mg, 500mg, 750mg and 1000mg, generic versions of UCB's Keppra tablets; omeprazole capsules 40mg, a generic version of AstraZeneca's Prilosec DR; lamotrigine CD chewable tablets 5mg and 25mg and lamotrigine tablets 25mg, 100mg, 150mg and 200mg, generic versions of GlaxoSmithKline's Lamictal; and divalproex capsules and delayed-release pellets 125mg, a generic version of Abbott's Depakote delayed-release capsules. Dr Reddy's has 69 ANDAs, addressing innovator sales of $47 billion, pending at the US FDA.
You may also be interested in...
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.